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Abstract
Nelfinavir is a potent HIV-protease inhibitor with pleiotropic effects in cancer cells. Experimental studies connect its anti-
cancer effects to the suppression of the Akt signaling pathway, but the actual molecular targets remain unknown. Using a
structural proteome-wide off-target pipeline, which integrates molecular dynamics simulation and MM/GBSA free energy
calculations with ligand binding site comparison and biological network analysis, we identified putative human off-targets
of Nelfinavir and analyzed the impact on the associated biological processes. Our results suggest that Nelfinavir is able to
inhibit multiple members of the protein kinase-like superfamily, which are involved in the regulation of cellular processes
vital for carcinogenesis and metastasis. The computational predictions are supported by kinase activity assays and are
consistent with existing experimental and clinical evidence. This finding provides a molecular basis to explain the broad-
spectrum anti-cancer effect of Nelfinavir and presents opportunities to optimize the drug as a targeted polypharmacology
agent.
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Introduction
Tremendous effort has been directed at rational drug design
where one strives to understand, and subsequently optimize,
how a small molecule interacts with a single protein target and
impacts a disease state. However, such approaches are less
fruitful in discovering effective and safe therapeutics to treat
complex diseases such as cancer. It is suggested that the
inhibition or activation of a single specific target may fail owing
to the inherent robustness of the underlying biological networks
causing the disease state [1,2,3,4,5,6]. The goal then is to
perturb multiple relevant targets. Perturbation may be achiev-
able through the use of drug cocktails, or possibly through a
single drug that has the appropriate polypharmacological effect
[1,2,4,6,7,8,9,10,11]. To rationally design such a drug is a very
complex problem that begins by identifying the targets to which
that drug binds. Here we address a much simpler problem, that
is, to take a drug that is already believed to show this effect and
attempt to explain why it might be so. Nevertheless, we must
still begin by identifying the multiple targets to which it binds.
To this end, we have developed an off-target pipeline to
identify protein-drug interaction profiles on a structural
proteome-wide scale. The off-target pipeline integrates our
previous chemical systems biology approach [12,13,14] with
algorithms that accurately estimate binding affinity. We then
use the target list predicted from the off-target pipeline to
suggest physiological outcomes from the associated biological
networks and determine how well these outcomes map to what
is observed clinically.
The extension to our previous approach presented here is to
better estimate the binding affinity in forming a protein-ligand
complex, as both experimental and theoretical studies suggest that
even weak binding to multiple targets may have profound impact
on the overall biological system [15,16,17]. Available computa-
tional tools that quantitatively study protein-ligand interactions are
based predominantly on protein-ligand docking and free energy
calculations for the protein-ligand complex [18,19]. A formidable
task then is to include protein flexibility into the binding affinity
calculation since errors in scoring mainly result from the use of
rigid protein conformations [20]. The modeling of protein
flexibility requires computationally intensive molecular dynamic
(MD) simulations. However, it is impractical to apply MD
simulation to the whole structural proteome. Our approach pre-
filters the structural proteome to find the most likely cases to apply
MD. Specifically, we undertake a human structural proteome-
wide ligand binding site comparison using previously developed
algorithms [21,22,23] and add intensive binding free energy
calculations, based on protein-ligand docking, MD simulation and
MM/GBSA free energy calculations.
We apply this strategy to explore the molecular mechanism for
the observed anti-cancer effect of Nelfinavir, a human immuno-
deficiency virus (HIV) protease inhibitor. Recently, Nelfinavir has
been repurposed for cancer treatment [24,25,26]. However, its
molecular targets remain unknown. The majority of published
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[27]. In human, the Akt family includes the serine/threonine
protein kinases Akt1, Akt2 and Akt3. These proteins are involved
in cell survival, protein synthesis and glucose metabolism and are
considered markers for many types of cancer [28,29,30]. Akt3 is
also known to be stimulated by platelet-derived growth factor
(PDGF), insulin and insulin-like growth factor 1 (IGF1) [31]. Thus
inhibition of the Akt pathway may also cause insulin resistance and
diabetes, a phenomenon observed as a side effect of treatment by
HIV protease inhibitors. Currently, there is no experimental
evidence to suggest that Nelfinavir binds directly to members of
the Akt family, rather it has been suggested that the drug acts
upstream of the Akt signaling pathway [32].
Using our structural proteome-wide off-target pipeline, we find
that multiple members of the protein kinase-like superfamily as off-
targets of Nelfinavir. Most of these protein kinases are found
upstream of the Akt, MAPK, JNK, NF-kB, mTOR and focal
adhesion pathways. We hypothesize that this weak but broad
spectrum protein kinase inhibition by Nelfinavir contributes to the
therapeutic effect against different types of cancer. Our hypothesis
is supported by kinase activity assays and consistent with other
existing experimental and clinical observations. This suggests that
the next challenges are specifically to optimize Nelfinavir as a
targeted polypharmacology agent, and more generally, to
determine whether our computational protocol can be applied
to other systems.
Results
Putative off-targets of Nelfinavir
The steps in our off-target pipeline are shown in Figure 1. In the
first step, the Nelfinavir binding pocket in the HIV protease dimer
structure (PDB Id: 1OHR) was used to search against 5,985 PDB
structures of human proteins or homologs of human proteins using
the SMAP software (see Supporting Information (SI) and methods
for details), which is based on a sensitive and robust ligand binding
site comparison algorithm [21,22,23]. Hits are considered
significant if the SMAP p-value ,1.0e-3. In step 2, the binding
poses and affinities of Nelfinavir to these putative off-targets are
estimated using two docking methods, Surflex [33] and eHiTs
[34], starting from the superimposed binding sites. If the docking
score indicates severe structural clashes between Nelfinavir and the
predicted binding pocket, the protein is removed from the off-
target list. After filtering by SMAP and the two docking programs,
92 putative off-targets remained for further analysis (SI, Table S1).
Among them, the top 7 ranked off-targets belong to the aspartyl
protease family that is the fusion form of the primary target HIV
protease dimer. The remaining 85 proteins belong to different
global folds from the primary target. These off-targets are
dominated by protein kinases (PKs) (51 off-targets) and other
ATP or nucleotide binding proteins (17 off-targets). The
distribution of the 51 protein kinases on the human kinome tree
[35] is shown in Figure 2. Even though these protein kinases have
a broad distribution among the different protein kinase families,
the majority of predicted off-targets belong to the tyrosine kinase,
cAMP-dependent, cGMP-dependent and protein kinase C
families. This distribution is more pronounced with a stringent
SMAP p-value smaller than 1.0e-4 (green in Figure 2). The 12 top-
ranked PKs with p-value smaller than 1.0e-4 were subject to
detailed protein-Nelfinavir docking and 10 of them were further
investigated through computational intensive molecular dynamic
simulations and MM/GBSA binding free energy calculations.
Predicted Nelfinavir binding to protein kinases
determined by protein-ligand docking
The SMAP alignments between the PKs and the Nelfinavir
binding sites reveal that ATP and its competitive inhibitors bind in
the vicinity of the predicted binding sites. An example is shown in
Figure 3 for the case of epidermal growth factor receptor (EGFR)
protein kinase domain (PDB id: 2J6M). The superimposed
Nelfinavir is accommodated in the protein kinase inhibitor
binding pocket and overlaps with the co-crystallized EGFR
inhibitor (PDB ligand id: AEE). If amino acid residues with
atomic distances less than 5.0 A ˚ to the inhibitors are considered as
the binding site, approximately 73% (16/22) of the known AEE
binding site residues are included in the predicated binding site of
Nelfinavir to EGFR.
Binding poses and affinities of Nelfinavir to the identified PK
binding sites are firstly estimated using the docking software eHiTs
[34] and compared to the binding affinities of co-crystallized
inhibitors in those PKs. The binding pose of Nelfinavir is
optimized from its superimposed conformation obtained from
the SMAP output rather than by an ab initio global conformational
search. Systematic errors in the scoring function are cancelled out
by using a normalized docking score (NDS) [13]. A large negative
value for the NDS indicates a higher likelihood of binding. The
predicated binding affinity of Nelfinavir is comparable to that of
co-crystallized inhibitors for several classes of PKs, notably EGFR
(SI Table S2). The NDS for EPHA2 is 1.328, which implies that
the docking score of Nelfinavir to EPHA2 is higher than for
randomly selected molecules. This protein was removed from
further calculations.
Ensemble average binding free energy estimation using
MD simulation
In order to get more accurate estimates for the binding affinities,
MM/GBSA calculations were performed on 10 PK hits filtered by
the SMAP binding site similarity search and ligand docking scores.
Since in reality binding is dynamic, the structure will adopt
different conformations during binding, and this should be
anticipated. Hence one should generate a statistically sufficient
ensemble from molecular-dynamics trajectories and compare the
resulting ensemble averages to obtain a more reliable binding free
energy value. Recent studies on MM/GBSA binding free energy
Author Summary
The traditional approach to drug discovery of ‘‘one drug –
one target – one disease’’ is insufficient, especially for
complex diseases, like cancer. This inadequacy is partially
addressed by accepting the notion of polypharmacology –
one drug is likely to bind to multiple targets with varying
affinity. However, to identify multiple targets for a drug is a
complex and challenging task. We have developed a
structural proteome-wide off-target determination pipe-
line by integrating computational methods for high-
throughput ligand binding site comparison and binding
free energy calculations to predict potential off-targets for
known drugs. Here this method is applied to identify
human off-targets for Nelfinavir, an antiretroviral drug with
anti-cancer behavior. We propose inhibition by Nelfinavir
of multiple protein kinase targets. We suggest that broad-
spectrum low affinity binding by a drug or drugs to
multiple targets may lead to a collective effect important
in treating complex diseases such as cancer. The challenge
is to understand enough about such processes so as to
control them.
Nelfinavir Weakly Inhibits Multiple Kinases
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sufficient to perform a meaningful MM/GBSA calculation
[36,37,38]. Here, the binding free energies averaged over 200
snapshots from the last 2 ns trajectory of an 8 ns MD simulation
are listed in Table 1 for the complex structures of protein kinases
bound with Nelfinavir and co-crystallized ligands. To estimate the
stability of the MD simulations, structural root-mean-square-
deviations (RMSDs) for receptor backbone atoms and ligand non-
hydrogen atoms are examined as a function of time (Supporting
Information Figure S1). The RMSD is calculated based on
superimposed structures fitting to the first frame of the 8 ns MD
simulation using the coordinates of the receptor backbone atoms.
Thus, RMSD values for the ligands reflect both internal and rigid
body movements relative to the protein. In all cases, RMSDs for
the receptor backbone atoms are well below 3 A ˚ for the last 2 ns
simulation, indicating robust simulations and reasonable samplings
for the MM/GBSA binding free energy calculation. The
conformational fluctuation of Nelfinavir bound to EPHB4 and
FGFR are higher than in other targets. Structural analysis of their
trajectories shows that Nelfinavir moves out of the binding pockets
of EPHB4 and FGFR during simulation, which indicates EPHB4
and FGFR may not be good candidates for Nelfinavir interaction.
Here, the MM/GBSA binding free energy calculation includes
gas-phase energies, solvation free energies and entropy contribu-
Figure 1. The structural proteome-wide off-target pipeline integrating ligand binding site characterization and comparison,
protein-ligand docking, MD simulation and MM/GBSA energy calculations, and biological network analysis.
doi:10.1371/journal.pcbi.1002037.g001
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solvation free energies, i.e., total binding enthalpy, are taken into
account, Nelfinavir shows comparable binding affinity to the co-
crystallized ligands. However, when considering the loss of entropy
during binding, Nelfinavir becomes less favorable than the co-
crystallized inhibitors due to its larger size and flexibility. For
example, when AEE enters the binding pocket of EGFR, the
entropy change for the whole system is 14.16 kcal/mol. However,
Figure 2. Distribution of predicted off-targets on the human kinome tree. Green represents off-targets with an SMAP p-value less than 1e-4.
Yellow represents off-targets with an SMAP p-value less that than 1e-3 and greater than 1e-4.
doi:10.1371/journal.pcbi.1002037.g002
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entropy losses for the whole system. Thus, even though the
entropy contribution is smaller than the enthalpy contribution, the
binding free energy difference between Nelfinavir and AEE comes
predominantly from the entropy change and this part of the free
energy cannot be omitted in providing a reliable estimate of
binding affinity.
Ligand binding pose and atomic interactions between ligand
and protein kinases are also important factors when measuring
ligand binding. The predicted binding pose of Nelfinavir
significantly overlaps with the known inhibitors of EGFR, IGF-
1R, FAK, Akt2, CDK2, ARK and PDK1 (SI, Figure S2 and S3).
The structure of Nelfinavir can be fragmented into five moieties:
the 2-methyl-3-hydroxy-benzamide portion A, the S-phenyl group
Figure 3. Overlap between EGFR ATP binding sites and Nelfinavir binding sites predicted by SMAP. The wheat cartoon represents the
backbone structure of EGFR (PDB id: 2J6M). Green sticks represent the co-crystal ligand of EGFR (PDB ligand id: AEE). Magenta sticks represent
superimposed Nelfinavir on EGFR according to SMAP alignment. Yellow sticks and balls represent the AEE binding site of EGFR. Orange sticks and
balls represent the predicted Nelfinavir binding site for EGFR. Blue sticks and balls represent the overlap between the AEE binding site and the
predicted Nelfinavir binding site for EGFR. The amino acid residues involved in the binding site are listed below the structure, colored accordingly.
doi:10.1371/journal.pcbi.1002037.g003
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droisoquinoline ring D and the central hydroxyl group E (SI,
Figure S4). The benzamide ring A in the predicted conformations
superimposes well onto the aromatic groups of the co-crystallized
inhibitors for these protein kinases, and plays a critical role in
molecular recognition [39]. For other predicted protein kinases,
the binding pose of Nelfinavir still partially overlaps with their
respective co-crystallized inhibitors and occupies the ATP-binding
pockets.
Most of the hydrogen-bond interactions and hydrophobic
interactions between protein kinases and co-crystallized inhibitors
could be found between Nelfinavir and the respective protein
kinases. As shown in Figure 4, the hydrogen bond between the
pyrrolopyrimidine core of AEE and the main chain amide of
Met793 on EGFR is maintained between benzamide hydroxy
O38 of Nelfinavir and the same atom on EGFR. This hydrogen
bond interaction is critical for protein-ligand binding in EGFR.
Missing this hydrogen bond will cause ,3,700-fold loss of
inhibitor potency in EGFR [40]. Residues that form hydrophobic
interactions with AEE are also close to Nelfinavir and provide
appropriate hydrophobic interactions as shown in Figure 4. These
conserved hydrogen bond interactions and hydrophobic interac-
tions support the binding of Nelfinavir to EGFR. Similar
conserved hydrogen bond interactions and hydrophobic interac-
tions are observed for other protein kinases, excluding FGFR,
EPHB4 and Abl, that is, where Nelfinavir partially overlaps with
the co-crystallized ligands. The binding free energies for Nelfinavir
to FGFR and EPHB4 also indicate that the binding affinities of
Nelfinavir to these two proteins are weaker than the other eight
protein kinases.
In summary, MM/GBSA binding free energy, ligand binding
pose, conserved hydrogen bond interactions and hydrophobic
interactions supports the direct interaction of Nelfinavir with
EGFR, which has been shown as a possible Nelfinavir target based
on ligand binding site similarity and from experimental studies by
others [25]. For FGFR, EPHB4 and Abl, the results from MD
simulation and MM/GBSA free energy calculations indicate that
Nelfinavir is unlikely to bind to these three targets. For other
targets, IGF-1R, FAK, Akt2, CDK2, ARK and PDK1, the
calculated binding free energies and predicted ligand binding
poses suggested the possible inhibition by Nelfinavir, even though
there is no experimental support at this time.
Protein kinase activity assay for EGFR and Akt families
Given that computationally EGFR and Akt2 show favorable
binding affinities for Nelfinavir, MD simulation and MM/GBSA
binding free energy calculations were extended to other members
of the EGFR (ErbB2, ErbB4) and Akt families (Akt1 and Akt3). As
shown in Figure 5, the binding free energies for EGFR, ErbB2,
ErbB4, Akt1, Akt2 and Akt3 are -15.60, -25.76, -31.83, -15.39, -
19.25 and -12.13 kcal/mol, respectively. A HTRFH Transcree-
nerTM ADP Assay of 20 mM Nelfinavir was undertaken for
EGFR, ErbB2, ErbB4 and Akt (Akt1, Akt2 and Akt3) in an effort
to verify the predictions from the MM/GBSA calculations. Weak
inhibition by Nelfinavir is detected for ErbB2 (Figure 5). The lower
binding free energy of ErbB2 is consistent with its higher inhibition
rate and the experimental and computational results both show
inhibition of the EGFR family by Nelfinavir. Considering that a
prescribed dose of Nelfinavir is 1,250 mg (2.2 mmol) (http://
www.rxlist.com/viracept-drug.htm), the plasma concentration of
Nelfinavir in HIV patients can reach 7-9 mM [41]. However, these
concentrations only achieve a partial reduction of cancer cell
proliferation and are not efficient in inducing apoptosis in cancer
cells. Most cellular activity studies require concentrations of
Nelfinavir greater than 20 mM [42]. At such high concentration,
Nelfinavir demonstrated specific anti-cancer activity with no
reports of non-specific binding. As such, it is not likely that the
specific in vivo and in vitro anti-cancer activity when using a high
concentration of Nelfinavir is due to its aggregation. Likewise,
when the same concentration of Nelfinavir is used in our kinase
assay, it is unlikely that Nelfinavir is aggregated [43]. Since the
assay may not be sensitive enough to detect weak bindings, most of
assay results are inconclusive. It is necessary to develop more
robust assay methods for determining weak bindings.
The inhibition of EGFRs by Nelfinavir is consistent with Gills
et al.’s work on exploring the effect of HIV protease inhibitors on
endogenous and growth factor induced Akt activation [25]. In
their study, 20 mM Nelfinavir reduced the activation of EGFR,
IGF-1R and Akt signaling pathways. The decreased phosphory-
lation of EGFR, IGF-1R and Akt directly in response to EGF or
IGF-1 indicates that Nelfinavir can compete with EGF or IGF-1
and act at the plasma membrane to inhibit growth factor
receptors. However, the inhibition of Akt activation by Nelfinavir
is weaker than that observed using a known PI3K inhibitor and
the effect is transient, which may suggest a weaker inhibition of
EGFR or IGF-1R by Nelfinavir. No obvious inhibition of Akt1
and Akt3 by 20 mM Nelfinavir is observed. Even though the ADP
assay was not applied to every predicted protein kinase, the
comparable computational results indicate the possibility that
Nelfinavir may also inhibit other protein kinases through weak
interactions.
Table 1. Calculated binding free energies from MM/GBSA
calculations for Nelfinavir and co-crystallized inhibitors for
predicted off-targets.
Ensemble average calculation
(kcal/mol)
Target Ligand DHbinding DTSbinding DGbinding
ARK HPM -41.50 -26.70 -14.80
ARK 1UN -41.62 -20.36 -21.26
ABL P16 -30.14 -14.09 -16.05
ABL 1UN -31.22 -20.41 -10.81
AKT2 I5S -35.67 -24.38 -19.25
AKT2 1UN -43.64 -35.67 -18.53
CDK2 1CD -52.68 -10.10 -42.58
CDK2 1UN -49.54 -21.67 -27.87
EGFR AEE -34.73 -14.16 -20.57
EGFR 1UN -33.72 -18.12 -15.60
EPHB4 7X4 -39.61 -17.64 -21.96
EPHB4 1UN -21.40 -19.86 -1.54
FAK BI9 -50.02 -18.82 -31.20
FAK 1UN -44.73 -16.20 -28.53
FGFR SU1 -35.88 -18.44 -17.44
FGFR 1UN -26.86 -21.24 -5.62
IGF-1R BMI -38.26 -17.28 -20.98
IGF-1R 1UN -31.43 -21.37 -10.05
PDK1 BI1 -35.39 -13.65 -21.74
PDK1 1UN -30.32 -17.76 -12.56
Ensemble averaged binding free energies calculated for 200 snapshots
extracted from the last 2 ns of the MD simulation.
doi:10.1371/journal.pcbi.1002037.t001
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Nelfinavir is the most potent inhibitor in cell proliferation and
Akt activation studies [25]. To compare Nelfinavir with other
protease inhibitors, MD simulation and MM/GBSA binding free
energy calculations were applied to two other protease inhibitors,
Saquinavir and Indinavir. Saquinavir has the most similar
inhibition effect to Nelfinavir in the cell proliferation analysis
involving 60 cell lines derived from nine different tumor types
and Indinavir has the weakest effect on cell proliferation [25].
Autodock Vina [77] was applied to get the starting structures for
Saquinavir and Indinavir when bound to EGFR, ErbB2 and
ErbB4. The docking energies for Nelfinavir, Saquinavir and
Indinavir are listed in SI Table S3 and show that there is no
significant difference between these three inhibitors. However,
the conserved hydrogen bond between Nelfinavir and EGFR
cannot be found for either Saquinavir or Indinavir. The
calculated MM/GBSA binding free energies for Saquinavir are
-8.51, -10.12 and -9.37 kcal/mol when bound to EGFR, ErbB2
and ErbB4, respectively and -1.11, -1.68 and -2.51 kcal/mol,
respectively, for Indinavir. Compared with the calculated MM/
GBSA binding free energies for Nelfinavir, the less negative
values for the binding free energies of Saquinavir indicate weaker
binding affinities. This is consistent with the observed effect of
these HIV protease inhibitors on Akt activity. The unfavorable
binding of Indinavir to the EGFR families is also supported
experimentally [25].
Effect of Nelfinavir off-target binding on Akt signaling
pathways
Putting together the results from the off-target predictions,
docking experiments, MD simulation, MM/GBSA free energy
calculations, and kinase activity assays, it appears that Nelfinavir
binds to different protein kinase (PK) off-targets through
relatively weak interactions. The majority of our top ranked
Figure 4. Comparative Interactions between EGFR and Inhibitor (PDB ligand id AEE; A) and EGFR and Nelfinavir (PDB ligand id
1UN; B). A: Cyan ribbon represents the backbone structure of EGFR bound to AEE (green). Cyan sticks represent the residues in contact with AEE.
Black dash line represents hydrogen bonding interactions between AEE and EGFR. The distance between N and N is 3.22 A ˚. B: Yellow ribbon
represents the backbone structure of EGFR bound to Nelfinavir. Yellow sticks represent the residues in contact with Nelfinavir. Black dash line
represents hydrogen bonding interactions between Nelfinavir and EGFR. The distance between N and O is 3.16 A ˚.
doi:10.1371/journal.pcbi.1002037.g004
Figure 5. Inhibition rates and calculated MM/GBSA binding free energies of Nelfinavir binding to EGFR, ErbB2, ErbB4, Akt1, Akt2
and Akt3.
doi:10.1371/journal.pcbi.1002037.g005
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kinase family, including EGFR, IGF-1R, Abl, FGFR and ephrin
receptor. The PKs in this family are high affinity cell surface
receptors that not only regulate normal cellular processes but also
play a critical role in the development of many types of cancers.
There are also other PKs identified as off targets for Nelfinavir,
such as CDK2, ARK2, FAK1, Akt2 and PDK1. By examining
pathways associated with each individual predicted off-target, we
constructed an integrated off-target interaction network (Figure 6).
To simplify the whole network, we only present the interactions
between predicted off-targets and the major pathways involved in
cancer development and insulin resistance. Effects of these off-
targets are not limited to these pathways. Predicted off-targets,
represented by yellow circles in the network, regulate PI3K,
MAPK, JNK, mTOR, NF-kB and focal adhesion pathways
through direct or indirect interactions with intermediate proteins
connecting the pathways. Inhibition of predicted off-targets is
predicted to down-regulate these pathways, and hence reduce
cancer risk and increase insulin resistance.
Consider EGFR as an example to show how inhibition by
Nelfinavir can result in an anti-cancer effect. Some major effects of
EGFR on cellular functions come from its regulation of the PI3K/
Akt pathway. As a receptor tyrosine protein kinase, EGFR can be
activated by epidermal growth factor and then induce activation of
Phosphoinositide 3-kinases (PI3K), resulting in the formation of a
PtdIns(3,4,5)P3 molecule (PIP3 in Figure 6). Akt will then bind to
PtdIns(3,4,5)P3 and be phosphorylated and activated by PDK1
and mTOR. As a consequence, the activation of Akt triggers the
downstream response of the Akt pathway, such as phosphorylation
of the Bcl-2-associated death promoter (BAD), activation of the
NF-kB pathway and inhibition of the retinoblastoma protein (Rb).
The inhibition of EGFR by Nelfinavir will reduce Akt signaling,
consistent with current experimental evidence. Along with the
regulation on the PI3K-Akt pathway, EGFR can also induce the
activation of the MAPK and JNK pathway through interaction
with Ras [44,45]. All these activities have the potential to increase
cell survival and cell proliferation and prevent cell apoptosis, as
shown in Figure 6. Conversely, over-activation of EGFR and the
associated down-stream pathways could result in uncontrolled cell
growth and division.
Other predicted off-targets of Nelfinavir, for example, IGF-1R,
Abl, FGFR, EPHB4 and FAK, have similar effects to EGFR,
again by controlling activation of PI3K and Ras. According to
our calculations, Nelfinavir can also bind to PDK1 and ARK.
While a different mechanism than EGFR inhibition, it is
hypothesized this can lead to regulation of the MAPK and
mTOR pathways. PDK1 is crucial for the activation of Akt
through direct phosphorylation.
CDK2 is also implicated by our off-target analysis. CDK2 is
part of the downstream regulation of the PI3K/Akt pathway, and
depending on cellular location, can either promote cell cycle
progression or cell death [46]. The presence of active nuclear
CDK2 during the transition to the G2 phase inhibits the cell cycle
progression while Akt-regulated nucleo-cytoplasmic CDK2-relo-
cation is required for cell cycle progression. The dual control of
CDK2 on cell proliferation and apoptosis makes it an interesting
anti-cancer target. Jiang et al. showed that Nelfinavir can inhibit
CDK2 activity in melanoma cells [30] in keeping with our
computational findings.
In summary, the dominant effect of Nelfinavir through off-
target binding to a variety of protein kinases comes from up-
stream regulation of the PI3K/Akt pathway. These protein kinases
are also hypothesized to regulate other cancer pathways such as
MAPK, JNK, NF-kB, mTOR and the focal adhesion pathway.
Similarly, Nelfinavir is predicted to inhibit IGF-1R, which
regulates the insulin/insulin-like growth factor signaling pathway,
and offers one possible explanation for the observed side effects of
Nelfinavir on insulin resistance and diabetes.
Figure 6. Interactions between predicted off-targets and PI3K/Akt, MAPK, JNK, NF-kB, mTOR, Glucose uptake, and Glycogenolysis
pathways. Yellow circles represent predicted off-targets. Blue circle represents intermediate proteins. Green squares represent pathways. Pink
squares represent cellular effects. Black lines represent activation. Red lines represent inhibition. Black dashed lines represent a dual effect (activation
or inhibition).
doi:10.1371/journal.pcbi.1002037.g006
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This study indicates that Nelfinavir is capable of a broad based
polypharmacological effect against a number of protein kinases as
targets. Determining the total number of possible targets is limited
by the availability of the 3-D structures (or models) of human
proteins. A second limitation might arise based on the versatility of
Nelfinavir itself. The binding sites determined here map to the
image of the ligand in the conformation it is found when bound to
an HIV-1 protease. It might bind to a different target using a
different conformation with higher affinity than observed here and
these would not be found since the binding pocket itself would be
different.
Given that existing experimental data indicate that the off-
targets to Nelfinavir are involved in the Akt pathway, other
potential strong binding off-targets upstream of the identified
receptor tyrosine kinases also need to be considered. One of the
most likely alternatives is the b-arrestin regulated G-protein
coupled receptor signaling transduction pathway which regulates
MAPKs, SRC, PI3K, and Akt, and mediates EGFR transactiva-
tion [47]. Two major non-kinase proteins involved in the kinase
regulation and transactivation of the GPCR signaling pathway are
the GPCR and b-arrestin. If the GPCR or b-arrestin is strongly
inhibited by Nelfinavir, it is expected that the cellular functions
such as GPCR internalization, translocation of smoothened to the
primary cilium, and chemotaxis control, which are mediated by
the b-arrestin, should be affected [47]. However, the related
phenotype changes have not been reported. In addition, no
significant hits (p-value ,1.0e-5) are found for Nelfinavir using the
Similarity Ensemble Approach (SEA), which is one of the most
sensitive methods to identify GPCR related off-targets [48,49].
The SMAP similarity between b-arrestin and HIV protease is not
significant (p-value .1.0e-2). Although more analyses are required
to determine if Nelfinavir binds to other proteins that indirectly
regulate EGFR pathways, the data reported here at least suggest
that the pleotropic effect of Nelfinavir comes from the direct
inhibition of a variety of protein kinases.
A fundamental question raised by this work is whether weak
binding of a drug to multiple targets can cumulatively cause strong
phenotypic changes? Existing studies of biological networks have
shown that the malfunction of multiple nodes more likely causes
the system to fail than the removal of a single node as a result of
diversity, redundancy and system control of the biological
network. Multiple node failures have been called ‘‘fail-on’’ [50],
and used to explain neurological disorders [51] and cancer [52,53]
in recent genome-wide studies. Addressing the fail-on phenome-
non would require a polypharmacological effect. The therapeutic
efficacy of multiple protein kinase inhibitors suggested here has
already been demonstrated by less specific protein kinase
inhibitors which attack tumors through multiple mechanisms
and are used in more than one type of cancer therapy [54]. For
example, Sunitinib is the first cancer drug simultaneously
approved for two different cancer treatments, namely, renal cell
carcinoma and imatinib-resistant gastrointestinal stromal tumor. A
protein kinase assay against 113 different kinases shows that
Sunitinib can bind to 73 additional kinases apart from its primary
target [55]. In another example, moderate micomolar RAF
inhibitor PLX4720 is potent in inhibiting downstream signaling
and proliferation of the cell harboring BRAF, and in treating
melanoma cell lines [56]. In contrast, Sorafenib that was
developed as a potent nanomolar RAF inhibitor failed in the
clinical trial due to its low anti-melonoma efficacy. Araujo et al.
demonstrated the synergistic effect of multiple low-dose inhibition
of upstream processes on the attenuation of downstream signals in
the EGFR signaling pathway [57], and suggested that low-dose
combination therapy may reduce drug side effects and resistances
in the treatment of cancer [58]. Nelfinavir is a potential lead
compound in the design of the next generation of anti-cancer
drugs. As indicated by the MM/GBSA binding free energies for
different protein kinases, the binding affinity of Nelfinavir is
weaker than for the original inhibitors. Entropy changes during
binding contribute significantly to the differences in binding
affinity since Nelfinavir consists of more rotatable bonds and is
more flexible than many small molecule protein kinase inhibitors.
Covalent bonds could be added to the Nelfinavir structure to
reduce the degree of freedom and increase the specificity and
binding affinity. On the other hand, it can be hypothesized that
the weak binding of Nelfinavir to multiple protein kinases helps
avoid severe side effects, but still impacts the system enough to
have a positive effect. That is, weak inhibition of multiple protein
kinases may be just enough to return the system to a normal state,
as suggest by dynamic analysis of model systems [57,58].
There are a number of unmet computational challenges in
exploiting the concept of multiple weak interactions and designing
selective polypharmacology therapeutics, from target identification
to lead optimization. Computational techniques that are able to
identify optimal combination targets and their inhibition windows
in cellular networks have been developed, but their scope is still
limited [59,60,61]. It is well accepted that an optimal lead should
balance binding potency and molecular size [62]. A highly potent
lead compound usually leads to a drug candidate with high
molecular weight, which is often linked to a higher risk of failure in
drug development [63]. Analysis of the binding affinity of
marketed drugs and natural products indicates that therapeutic
efficacy is not necessarily associated with high binding affinity [63].
Moreover, drug-target interactions in vivo are different from those
in vitro. An increasing body of evidence suggests that the drug-
target residence time, a measurement of the lifetime of the drug-
target complex, better correlates to drug efficacy than does the
binding affinity [64,65]. This suggests that lead optimization
should focus on the drug-target residence time instead of binding
affinity. Although methodologies have been proposed for multi-
target screening based on binding affinity [66], there are simply no
computational tools available for the efficient and accurate a priori
estimation of the drug-target residence time from molecular
structures.
A detailed understanding of the effect of multiple interactions on
the biological network requires innovative systems biology
approaches. The qualitative description of the biological network
presented here is limited in its predictive power, considering the
highly dynamic nature of signal transduction pathways. A
mathematical modeling approach will be more powerful than
the static approach as we have demonstrated recently in a study of
CETP inhibitors [67]. Existing mathematical modeling methods
such as ordinary differential equations, Petri nets, and pi-calculus
require a large number of kinetics parameters to simulate the
dynamic behavior of the biological system [68]. In practice many
of these parameters may not be available. Thus the network model
has to be reduced. The qualitative properties derived from off-
target binding network may help to develop restrained but
functional dynamic models that are suitable for parameter
optimization and mathematical modeling.
In conclusion, by integrating methods from structural bioinfor-
matics, molecular modeling and network analysis, we propose that
the observed anti-cancer effects of the HIV protease inhibitor
Nelfinavir derive from weak binding to multiple protein kinases
that are mostly upstream of the PI3K/Akt pathway. Our
computational approach, enhanced from previous work with the
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supported by kinase activity assays and existing experimental and
clinical evidence. This type of approach has the potential to be
generalized as a form of rational polypharmacological drug design.
Materials and Methods
Overview of structural proteome-wide off-target pipeline
The structural proteome-wide off-target pipeline is outlined in
Figure 1. Firstly, the Nelfinavir binding pocket in the HIV
protease (PDB Id: 1OHR) was used to search against 5,985 PDB
structures of human proteins or homologous of human proteins
using the SMAP software [21,22,23]. Secondly, the binding poses
and affinities of Nelfinavir to these putative off-targets are
estimated using two docking methods, Surflex [33] and eHiTs
[34]. If the docking score indicates severe structural clashes
between Nelfinavir and the predicted binding pocket, the protein
is removed from the off-target list. Finally, the remaining putative
off-targets are subject to MD simulation, MM/GBSA calculation,
network reconstruction, and kinase activity assay.
Ligand binding site similarity search
5,985 PDB structures that are homologous to human proteins
(sequence identify .30%, alignment coverage larger than 90%)
are searched against the HIV-1 protease dimer (PDB id: 1OHR)
using SMAP, which can be downloaded from http://funsite.sdsc.
edu. The detailed algorithms implemented in SMAP are presented
elsewhere [21,22,23]. In brief, proteins are represented using Ca
atoms only and characterized by a geometric potential [21]. Then
two proteins are aligned to identify similar local binding sites using
the Sequence Order Independent Profile-Profile Alignment
(SOIPPA) algorithm [22]. The statistical significance of the
binding site similarity is estimated using an extreme value
distribution model [23].
Reverse docking of the human structural proteome
The binding affinity of Nelfinavir to the putative off-targets with
SMAP p-value less than 1.0e-3 are estimated by two docking
methods, Surflex [33] and eHiTs [34]. First, the complex structure
of HIV-1 protease with Nelfinavir is superimposed onto these
proteins according to the SMAP alignment. The superimposed
structure of Nelfinavir is used as the starting conformation for
docking. The binding pose of Nelfinavir in these statistically
significant off-targets is locally optimized and scored starting from
the starting conformation using Surflex 2.1 (default setting) and
eHits 6.2 (the fastest setting). The docking score is normalized
using the protocol described in reference [13].
MD simulation and MM/GBSA binding free energy
calculation
MM/GBSA [69,70] was developed for free energy calculations
and has been used to estimate the binding affinity for several
protein or DNA systems [71,72,73,74]. Here we perform ensemble
average MM/GBSA binding free energy calculation on the
snapshots from the MD simulation to compare binding affinity of
Nelfinavir with that of the co-crystallized ligands.
MD simulation on the complex structures of predicted
protein kinase off-targets and their inhibitors including
Nelfinavir
Explicit solvent molecular dynamics simulations were per-
formed with NAMD [75] on the structures of the Nelfinavir-
protein kinase complexes and co-crystallized ligand-protein kinase
complexes. The starting structure for Nelfinavir in each protein
kinase is the lowest energy conformation obtained through
Autodock Vina [76]. These complex structures are embedded in
rectangular boxes of TIP3P water [77] molecules to mimic the
solvent environment. The smallest distances between the edge of
the boxes and the atoms of the complex structures are adjusted to
be at least 10 A ˚. Ions are added to neutralize these systems and
satisfy the salt concentrations. The salt concentration is obtained
from individual experimental condition for each protein kinase.
The long distance cut-off for both van der Waals interactions and
electrostatic interactions is set as 14 A ˚. A switching function is used
to truncate the van der Waals energy smoothly at the cut-off
distance. The Particle Mesh Ewald (PME) [78] method is applied
to treat the long range electrostatic interactions. All covalent bonds
involving hydrogen atoms are constrained by the SHAKE
algorithm [79]. In order to simulate the NPT ensemble (system
with a fixed pressure P, temperature T, and number of atoms N),
the Langevin piston Nose-Hoover method [80,81] in NAMD
together with the periodic boundary conditions is used to maintain
a constant pressure and temperature for these systems.
Systems are first minimized by a five-stage minimization
protocol. Hydrogen atoms are optimized in the first stage, keeping
all other atoms fixed. Then water molecules and side chain atoms
are relaxed in the second and third stage, respectively. All atoms
are optimized in the fourth stage, with position restraints on
backbone atoms of proteins and ligands. Minimization is
completed by an additional 25,000 steps, without any restraints,
to remove bad contacts. All minimizations are preformed with the
conjugate gradient energy minimization method [82] in NAMD.
The optimized systems are then gradually heated from 0 K to
50K, 100 K, 150 K, 200 K, 250 K, and experimental temperature
(about 298 K) with position restraints on the backbone atoms. The
structures are equilibrated at each temperature for 250 ps with a 1.0
fs time step. The force constant of restraints is 4.0 kcal/mol?A ˚ -2.
After the systems are heated to the experimental temperature,
positionrestraints areremoved inthe following120pssimulation by
gradually reducing the force constant. Subsequently 8 ns NPT MD
simulations are carried out on these systems with 1.0 fs time step at
the experimental temperature. 200 snapshotsare extracted from the
last 2 ns simulations with 10.0 ps time intervals to generate
representative configurations for the MM/GBSA binding free
energy calculation.
MM/GBSA calculation
The binding free energy can be calculated through the following
equation:
DGbinding~Gcomplex{Greceptor{Gligand ð1Þ
where Gcomplex, Greceptor, Gligand are the free energies of the complex,
receptor and ligand respectively. The free energy of each
molecular on the right hand side can be considered as the sum
of molecular mechanical energy in gas phase, solvation energy and
entropy term, as shown in the following formula:
Gmolecular~EMMzGsol{TS ð2Þ
EMM is calculated by the molecular mechanics method with
standard force field parm9 in AMBER9 package [83,84]. The
electrostatic contribution to the solvation free energy is determined
by the Generalized Born (GB) model [85,86,87,88], a widely used
continuum solvent model. The ‘‘OBC’’ model with modified
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calculate this part of energy. This model is newer than the original
version of the GB model and provides a significant improvement
and is recommended for both proteins and nucleic acids. The
interior dielectric constant of the molecule of interest is set as 1.0
and the exterior or solvent dielectric constant is set as 78.5. The
non-polar contribution to the solvation free energy is proportional
to the solvent-accessible surface area [89,92]. The surface area is
calculated by the LCPO model [93] and the surface tension used
to calculate the non-polar part is taken as 0.0072 kcal/mol?A ˚ -2.
The entropic term is the most time-intensive part of the MM/
GBSA calculation but is found to be indistinguishable among
different conformational states and contributes less than the other
two terms in many application for estimating relative binding free
energies [69,94,95]. The entropy change associated with ligand
binding is estimated by normal mode analysis [96] in AMBER9.
For each system, the MM/GBSA calculation is carried out on the
200 snapshots extracted from the last 2ns of the MD simulation.
Protein kinase activity assay
HTRFH TranscreenerTM ADP Assays were performed on
EGFR, ErbB2 and ErbB4 Akt1, Akt2 and Akt3 by GenScript
(New Jersey, U.S.A). Nelfinavir Mesylate was purchased from
Toronto Research Chemicals (North York, Canada). The
compound is diluted to a 10 mM concentration with acetone
and stored at -20uC. Inhibition of Nelfinavir at 20 mM was tested
on EGFR, ErbB-2, ErbB-4 and Akt (Akt1, Akt2, Akt3).
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